Last reviewed · How we verify

Ademetionine tablet — Competitive Intelligence Brief

Ademetionine tablet (Ademetionine tablet) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amino acid derivative / Methyl donor. Area: Hepatology / Gastroenterology.

phase 3 Amino acid derivative / Methyl donor S-adenosylmethionine (SAM) pathway Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ademetionine tablet (Ademetionine tablet) — Abbott. Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ademetionine tablet TARGET Ademetionine tablet Abbott phase 3 Amino acid derivative / Methyl donor S-adenosylmethionine (SAM) pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amino acid derivative / Methyl donor class)

  1. Abbott · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ademetionine tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ademetionine-tablet. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing